ClarusC64/clinical-fragility-buffering-mechanism-mapping-v0.1
Resilience-Enhancing Pharmacopeia Index README Core premise Some drugs work across diseases because they increase system capacity, not because they hit a target. This collection defines, measures, and deploys that class of drugs. Not pathology-first. Resilience-first. What this pharmacopeia tests Does a drug broaden the healthy basin Which fragility axes it buffers Who should receive it based on systemic vulnerability These datasets do not ask “Does this drug treat condition X” They ask “Does… See the full description on the dataset page: https://huggingface.co/datasets/ClarusC64/clinical-fragility-buffering-mechanism-mapping-v0.1.
Resilience-Enhancing Pharmacopeia
Index README
Core premise
Some drugs work across diseases because they increase system capacity, not because they hit a target.
This collection defines, measures, and deploys that class of drugs.
Not pathology-first. Resilience-first.
What this pharmacopeia tests
Does a drug broaden the healthy basin
Which fragility axes it buffers
Who should receive it based on systemic vulnerability
These datasets do not ask “Does this drug treat condition X”
They ask “Does this drug make the system harder to break”
The Trinity
- Systemic Resilience Gain Profiling
Path ClarusC64/clinical-systemic-resilience-gain-profiling-v0.1
What it establishes
resilience gain under stress
operating range widening
recovery speed after perturbation
durability of benefit
Core output
Is this drug a capacity builder or just symptom control
This is the entry gate.
- Fragility Buffering Mechanism Mapping
Path ClarusC64/clinical-fragility-buffering-mechanism-mapping-v0.1
What it explains
which fragility axes are reinforced
how buffering is achieved
what tradeoffs are introduced
Axes include
inflammaging
mitochondrial reserve
autonomic flexibility
stress-response coherence
This separates true resilience from cosmetic calm.
- Resilience-First Indication and Patient Matching
Path ClarusC64/clinical-resilience-first-indication-patient-matching-v0.1
What it deploys
patient selection based on fragility profile
off-label use with structural justification
contraindication awareness
This enables prescribing by system need, not diagnosis.
How these sets connect to the wider Clarus ecosystem
These datasets integrate directly with
Fragility Amplification Detection
Basin Constraint Mapping
Therapeutic Niche Synthesis
Polypharmacy Coherence Matrix
Together they form a loop
Measure capacity
Explain buffering
Match patient
Monitor stability
What this enables that did not exist before
A defensible category of resilience-enhancing drugs
Safer off-label use grounded in structure
Early identification of patients at systemic risk
Drug development framed as basin widening, not target pursuit
This is not incremental improvement.
It is a new pharmacological lens.
Intended users
translational medicine teams
aging and longevity programs
complex chronic disease clinics
pharma discovery groups exploring non-target effects
regulators evaluating off-label rationale
Summary
These datasets answer three questions in order
Does the drug increase resilience
How does it do so
Who should receive it
If any one fails the chain breaks
If all three hold a new class of medicine becomes legible.